Atezolizumab plus bevacizumab vs sorafenib in locally advanced or metastatic hepatocellular carcinoma: The randomised phase III study IMbrave150

被引：0
|
作者：
Ducreux, M. P. [1 ]
Cheng, A-L. [2 ]
Qin, S. [3 ]
Zhu, A. X. [4 ]
Ikeda, M. [5 ]
Kim, T-Y. [6 ]
Xu, D-Z. [7 ]
Verret, W. [8 ]
Liu, J. [7 ]
Finn, R. S. [9 ]
Galle, P. R. [10 ]
机构：
[1] Gustave Roussy, Med Oncol, Villejuif, France
[2] Natl Taiwan Univ Hosp, Med Oncol, Taipei, Taiwan
[3] Peoples Liberat Army Canc Ctr, Med Oncol, Nanjing, Jiangsu, Peoples R China
[4] Harvard Med Sch, Massachusetts Gen Hosp, Boston, MA 02115 USA
[5] Natl Canc Ctr Hosp East, Med Oncol, Kashiwa, Chiba, Japan
[6] Seoul Natl Univ, Med Oncol, Coll Med, Seoul, South Korea
[7] F Hoffman La Roche Ltd, Roche Prod Dev, Shanghai, Peoples R China
[8] Genentech Inc, Prod Dev Oncol, San Francisco, CA 94080 USA
[9] Univ Calif Los Angeles, Geffen Sch Med, Los Angeles, CA USA
[10] Univ Med Ctr Mainz, Med Dept 1, Mainz, Germany
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
782TiP
引用
收藏
页码：267 / 267
页数：1
相关论文
共 50 条
  • [21] Impact of Bevacizumab Being Skipped due to Adverse Events of Special Interest for Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab: An Exploratory Analysis of the Phase III IMbrave150 study
    Kudo, Masatoshi
    Tsuchiya, Kaoru
    Shao, Yu-Yun
    Finn, Richard S.
    Galle, Peter R.
    Ducreux, Michel
    Cheng, Ann-Lii
    Yamashita, Tatsuya
    Koga, Hironori
    Take, Ryosuke
    Yamada, Kyoko
    Asakawa, Takashi
    Nakagawa, Yuki
    Ikeda, Masafumi
    LIVER CANCER, 2024, 13 (04) : 401 - 412
  • [22] IMbrave150: exploratory efficacy and safety results of atezolizumab plus bevacizumab vs sorafenib in patients (pts) with unresectable hepatocellular carcinoma (HCC) who had prior locoregional therapy (LRT)
    Qian, Yuquan
    Liu, Baojiang
    Weiss, Christel
    Zhu, Xu
    Teufel, Andreas
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 79 - 79
  • [23] IMbrave150: updated overall survival (OS) data from a global, randomized, open-label Phase III study of atezolizumab (atezo) plus bevacizumab (bev) vs sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC)
    Galle, P.
    Finn, R. S.
    Qin, S.
    Ikeda, M.
    Ducreux, M.
    Kim, T. -Y
    Lim, H. Y.
    Kudo, M.
    Breder, V
    Merle, P.
    Kaseb, A.
    Li, D.
    Verret, W.
    Shao, H.
    Liu, J.
    Li, L.
    Zhu, A. X.
    Cheng, A. -L
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 34 - 34
  • [24] Effect of early antibiotic exposure on survival of patients receiving atezolizumab plus bevacizumab but not sorafenib for unresectable HCC: A sub-analysis of the phase III IMbrave150 study.
    Fulgenzi, Claudia A. M.
    Murphy, Cian
    D'Alessio, Antonio
    Scheiner, Bernhard
    Pinter, Matthias
    Cortellini, Alessio
    Pinato, David J. James
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 597 - 597
  • [25] Early response and safety of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma in patients who do not meet IMbrave150 eligibility criteria
    Sho, Takuya
    Suda, Goki
    Ogawa, Koji
    Kimura, Megumi
    Kubo, Akinori
    Tokuchi, Yoshimasa
    Kitagataya, Takashi
    Maehara, Osamu
    Ohnishi, Shunsuke
    Shigesawa, Taku
    Nakamura, Akihisa
    Yamada, Ren
    Ohara, Masatsugu
    Kawagishi, Naoki
    Natsuizaka, Mitsuteru
    Nakai, Masato
    Morikawa, Kenichi
    Furuya, Ken
    Baba, Masaru
    Yamamoto, Yoshiya
    Suzuki, Kazuharu
    Izumi, Takaaki
    Meguro, Takashi
    Terashita, Katsumi
    Ito, Jun
    Miyagishima, Takuto
    Sakamoto, Naoya
    HEPATOLOGY RESEARCH, 2021, 51 (09) : 979 - 989
  • [26] Letter regarding "Impact of Bevacizumab Being Skipped due to Adverse Events of Special Interest for Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab: An Exploratory Analysis of the Phase III IMbrave150 Study"
    Hatanaka, Takeshi
    Hiraoka, Atsushi
    Tada, Toshifumi
    Kakizaki, Satoru
    LIVER CANCER, 2024,
  • [27] Patient-reported outcomes (PROs) from the Phase III IMbrave150 trial of atezolizumab (atezo) plus bevacizumab (bev) vs sorafenib (sor) as first-line treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC)
    Galle, Peter R.
    Finn, Richard S.
    Qin, Shukui
    Ikeda, Masafumi
    Zhu, Andrew X.
    Kim, Tae-You
    Kudo, Masatoshi
    Breder, Valeriy Vladimirovich
    Merle, Philippe
    Kaseb, Ahmed Omar
    Li, Daneng
    Mulla, Sohail
    Verret, Wendy
    Xu, Derek-Zhen
    Hernandez, Sairy
    Liu, Juan
    Huang, Chen
    Lim, Ho Yeong
    Cheng, Ann-Lii
    Ducreux, Michel
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [28] Thyroid dysfunction after atezolizumab and bevacizumab is associated with favorable outcomes in hepatocellular carcinoma (IMbrave150 and Korean patients cohorts)
    Chon, H.
    Song, Y. S.
    Yang, H.
    Kim, I.
    Hye-Young, K.
    Lee, W. S.
    Sang, Y. B.
    Kim, C.
    ANNALS OF ONCOLOGY, 2023, 34 : S611 - S611
  • [29] IMbrave152/SKYSCRAPER-14: a Phase III study of atezolizumab, bevacizumab and tiragolumab in advanced hepatocellular carcinoma
    Badhrinarayanan, Shreya
    Cotter, Christopher
    Zhu, Huaqi
    Lin, Ya-Chen
    Kudo, Masatoshi
    Li, Daneng
    FUTURE ONCOLOGY, 2024,
  • [30] IMbrave150: updated efficacy and safety by risk status in patients (pts) receiving atezolizumab (atezo) plus bevacizumab (bev) vs sorafenib (sor) as first-line treatment for unresectable hepatocellular carcinoma (HCC)
    Finn, Richard S.
    Qin, Shukui
    Ikeda, Masafumi
    Galle, Peter R.
    Ducreux, Michel
    Mertens, Joachim
    Kim, Tae-You
    Kudo, Masatoshi
    Lim, Ho Yeong
    Breder, Valeriy
    Merle, Philippe
    Kaseb, Ahmed
    Li, Daneng
    Feng, Yin-Hsun
    Verret, Wendy
    Nicholas, Alan
    Li, Lindong
    Ma, Ning
    Zhu, Andrew X.
    Cheng, Ann-Lii
    SWISS MEDICAL WEEKLY, 2021, 151 : 25 - 26
12345